Gannet BioChem, a leading specialty chemical Contract Development and Manufacturing Organization (CDMO), has received validation from the Science Based Targets initiative (SBTi). This milestone confirms the company’s commitment to reducing greenhouse gas (GHG) emissions responsibly and aligns with global climate goals.
The validation includes Gannet BioChem’s targets to cut absolute Scope 1 and 2 GHG emissions by 63 percent by 2035, using 2020 as the baseline year. The company also aims to measure and reduce Scope 3 emissions across relevant categories.
Nicholas Shackley, CEO, stated that Gannet BioChem supports discovery programs and enables commercial biomanufacturing in the field of activated polymers and bioconjugation. He emphasized that the company’s responsibility extends to both therapeutic innovation and environmental impact.
Shackley added that having their targets validated by SBTi encourages the company to stay on the right path. It also motivates continuous efforts to improve sustainability practices across operations.
Gannet BioChem has been developing a science-led sustainability framework emphasizing transparency and ongoing progress. The company is working to increase energy efficiency at key sites and explore renewable energy options. It is also strengthening processes to measure and manage Scope 3 emissions and building responsible sourcing partnerships.
These initiatives form part of a multi-year roadmap aimed at reducing the environmental footprint while supporting the growing needs of the pharmaceutical and life sciences sectors. Gannet BioChem’s efforts demonstrate its dedication to responsible growth and positive environmental impact.
